Whalesbook
Bengaluru Plant par USFDA ki nazar
Strides Pharma Science ka jo Bengaluru mein main manufacturing plant hai, wahan routine inspection mein USFDA ne paanch observations nikali hain. Inspection 20 May, 2026 ko khatam hui aur company ko ek Form 483 mila hai jismein saari baatein likhi hain.
Company ne kaha hai ki woh 15 din ke andar iss regulatory deadline ko poora karenge aur shareholders ko updates dete rahenge.
Is news ke baad, Strides Pharma Science ka stock BSE par ₹1,145.00 par close hua, jo 0.75% kam tha. Investors USFDA inspection ke outcomes ko lekar kaafi sensitive rehte hain.
Pehle bhi hui hai USFDA se baat
Ye pehli baar nahi hai jab Strides Pharma ko USFDA ki taraf se kuch sunna pada ho. February 2026 mein, company ke New York wale plant ko Voluntary Action Indicated (VAI) classify kiya gaya tha. Iska matlab hai ki FDA ko issues toh mile, lekin unhein itna serious nahi maana gaya ki turant koi formal action liya jaaye.
Usse pehle, December 2025 mein, New York facility ki inspection mein chaar procedural observations aayi thi, lekin usse commercial products ki supply mein koi fark nahi pada tha.
Market Performance aur Industry ka Scene
Strides Pharma Science ke stock ne ab tak acha perform kiya hai, May 20, 2026 tak 66.03% ka 1-year return diya hai. Company ki market cap lagbhag ₹10,594.30 crore thi.
USFDA Form 483 observations pharma companies ke liye normal hain, jismein corrective action plans banane padte hain. Strides ka pehle ka experience hai aise cheezein handle karne ka.
19.0x ke Price-to-Earnings (P/E) ratio (TTM) par, Strides Pharma ka valuation Indian pharma sector ke median P/E ratio (30.79 times) se kaafi kam hai, jo ki ek discount dikhata hai.
Indian pharma sector mein overall, US manufacturing capabilities aur supply chain risks kam karne ki baatein chal rahi hain. Strides ka operational performance bhi strong raha hai, Q4 FY26 mein profit 51% badha tha aur FY26 ke liye ₹5 per share ka dividend propose kiya gaya hai.
Concerns aur Purane Cases
Lagatar paanch observations ek important facility mein, thoda sochne wala point hai. July 2019 mein Puducherry facility mein manufacturing records ke "uncontrolled destruction" ko lekar FDA warning letter mil chuki hai, jo documentation aur quality control ki problems ko dikhata hai. Us wajah se stock 8% gira tha.
Puducherry facility ko pehle 'OAI' classify kiya gaya tha, phir February 2023 mein 'VAI' mein change hua, jo uss waqt ki seriousness batata hai.
Halanki, current observations ko procedural bataya ja raha hai, lekin ek flagship facility par itne saare points alag systemic issues ki taraf ishara kar sakte hain. Pharma industry mein stringent cGMP rules follow karne hote hain, aur koi bhi deviation supply aur investor confidence ko affect kar sakta hai.
Strides Pharma ne Q4 FY26 mein 11% revenue increase aur lagbhag 51% profit growth report kiya hai, lekin alag alag facilities par observations ka pattern quality management systems ko improve karne ki zarurat bata sakta hai. Ye concern aur bhi important ho jata hai jab market competitive ho aur regulatory compliance sabse upar ho.